
Opinion|Videos|December 3, 2024
The Impact of Biomarkers and Modern Disease-Modifying Therapies in MS
Author(s)Gabriel Pardo, MD, FAAN, Martin Belkin, DO
Panelists discuss how modern multiple sclerosis (MS) management has evolved from symptomatic treatment to a proactive, personalized approach leveraging advanced biomarkers and sophisticated disease-modifying therapies. The focus has shifted toward early intervention, precise monitoring, and comprehensive disease control, significantly improving patient outcomes and quality of life.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please share how your management of MS has changed in recent years with the availability of biomarkers and highly efficacious disease-modifying therapies.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease
2
NeuroVoices: Robert Alexander, MD, on the Evolution of Antiamyloid Therapeutics in Alzheimer Disease
3
Neflamapimod Reduces Plasma GFAP in Dementia With Lewy Bodies, Showing Correlation With Clinical Improvement
4
Additional Insights From the U.S. POINTER Study at CTAD 2025: Heather M. Snyder, PhD
5


































